This Article Full Text Full Text (PDF) All Versions of this Article: 29/2/155    most recent Final Manuscript Author Manuscript Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Google Scholar Articles by Kearns, A. E. Articles by Kostenuik, P. J. PubMed PubMed Citation Articles by Kearns, A. E. Articles by Kostenuik, P. J.

Receptor Activator of Nuclear Factor B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease

Endocrine Research Unit (A.E.K., S.K.), Mayo Clinic College of Medicine, Rochester, Minnesota 55905; and Metabolic Disorders Research (P.J.K.), Amgen Inc., Thousand Oaks, California 91320

Correspondence: Address all correspondence and requests for reprints to: Paul J. Kostenuik, Amgen Inc., 1 Amgen Center Drive, M/S 15-2-B, Thousand Oaks, California 91320. E-mail: paulk{at}amgen.com

Osteoclasts and osteoblasts dictate skeletal mass, structure, and strength via their respective roles in resorbing and forming bone. Bone remodeling is a spatially coordinated lifelong process whereby old bone is removed by osteoclasts and replaced by bone-forming osteoblasts. The refilling of resorption cavities is incomplete in many pathological states, which leads to a net loss of bone mass with each remodeling cycle. Postmenopausal osteoporosis and other conditions are associated with an increased rate of bone remodeling, which leads to accelerated bone loss and increased risk of fracture. Bone resorption is dependent on a cytokine known as RANKL (receptor activator of nuclear factor B ligand), a TNF family member that is essential for osteoclast formation, activity, and survival in normal and pathological states of bone remodeling. The catabolic effects of RANKL are prevented by osteoprotegerin (OPG), a TNF receptor family member that binds RANKL and thereby prevents activation of its single cognate receptor called RANK. Osteoclast activity is likely to depend, at least in part, on the relative balance of RANKL and OPG. Studies in numerous animal models of bone disease show that RANKL inhibition leads to marked suppression of bone resorption and increases in cortical and cancellous bone volume, density, and strength. RANKL inhibitors also prevent focal bone loss that occurs in animal models of rheumatoid arthritis and bone metastasis. Clinical trials are exploring the effects of denosumab, a fully human anti-RANKL antibody, on bone loss in patients with osteoporosis, bone metastasis, myeloma, and rheumatoid arthritis.

This article has been cited by other articles:

				J. N. Hirschhorn and L. Gennari Bona Fide Genetic Associations with Bone Mineral Density N. Engl. J. Med., May 29, 2008; 358(22): 2403 - 2405. [Full Text] [PDF]

				U. Styrkarsdottir, B. V. Halldorsson, S. Gretarsdottir, D. F. Gudbjartsson, G. B. Walters, T. Ingvarsson, T. Jonsdottir, J. Saemundsdottir, J. R. Center, T. V. Nguyen, et al. Multiple Genetic Loci for Bone Mineral Density and Fractures N. Engl. J. Med., May 29, 2008; 358(22): 2355 - 2365. [Abstract] [Full Text] [PDF]